ECP 2019 Final Programme

Sunday, 8 Sept 89 ECP 2019 · Nice Poster Sessions a Sunday PS-04 014 Concordance of Ventana SP218 PTEN IHC and CST138G6 PTEN IHC assays with known PTEN genetic status in prostate cancer Rebecca Fish, United Kingdom P. Scorer, P. Lao-Sirieix, M. Kockx, E. de Bruin, M. Roudier, A. Sharp, B. Ehrhardt, C. Barker 015 Somatic mutations in KRAS, NRAS and BRAF genes in patients with colorectal cancer from Lower Silesia Region – a preliminary report Lukasz Fulawka, Poland L. Hajac, M. Glosna, D. Michalowska 016 NSD2 promotes triple-negative breast cancer cell proliferation, migration and invasion by inhibiting TIMP3 expression Bo Gao, China Y. Li, Y. Pan 017 EZH2-miR-26a-5p-NSD2 axis contributes to cell proliferation and DNA repair and inhibit cell apoptosis in diffuse large B-cell lymphoma Bo Gao, China Y. Pan, Y. Li 018 KRAS / NRAS and BRAF molecular characterisation through Next-Generation Sequencing (NGS) techniques in colorectal cancer Monica González Farré, Spain M. C. Fernández Rodríguez, L. Masfarre, G. M. Parini, N. Navarro, E. Moragón, G. Piquer, R. Rueda, J. Gimeno, D. Naranjo Hans, B. Bellosillo, B. Lloveras, M. Iglesias 019 Inflammation slightly increases PCA3 which does not affect its contribution to the refinement of prostate biopsy decision making in combination with percentage of free PSA, AMACR, EPCAM and PSGR Zlata Huskova, Czech Republic J. Knillova, M. Kral, Z. Kolar, J. Bouchal 020 Discovering triggers of IgA nephropathy progression by Matrix-assisted laser deso- rption/ionisation mass spectrometry imaging Mariia Ivanova, Italy O. Dyadyk, A. Smith, F. Magni 021 Fast immunofluorescence multiplexing using a microfluidic precision autostainer and tyramide signal amplification Alexandre Kehren, Switzerland S. Adnane, B. Pelz, S. Brajkovic, C. Hoyt, D. Dupouy 022 A comparative study of “PD-L1-CAD-test” (BIOCAD) and “PD-L1 IHC 22C3 pharmDx kit” (Dako) Olga Kuznetsova, Russia G. Frank, L. Zavalishina, Y. Andreeva, L. Moskvina 024 Elevated TCRB repertoire convergence and clonal expansion in the NSCLC tumour microenvironment of responders to anti-PD-1 monotherapy Timothy Looney, USA K. Leonards, I. Alborelli, L. Quagliata, P. M. Jermann 025 Immunocytochemical detection of selected proteins in myeloma cells after their treatment with epigenetic modulators Petra Luzna, Czech Republic K. Cizkova, Z. Kolar, K. Smesny Trtkova 026 Silencing of E-cadherin in colorectal cancer cells changes their sensitivity to chemotherapy Monika Manethova, Czech Republic J. Soukup, V. Skarkova 027 Acquired resistance mechanisms to EGFR tyrosine kinase inhibitors in lung cancer: coexistence of T790M with phenotypic small cell transformation Javier Martin Lopez, Spain P. Martin Acosta, E. Tejerina Gonzalez, D. Garcia Fresnadillo, Y. Vicente Lago, L. Martin, M. Exposito Alcaide, C. Salas Anton